Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hereditary Angioedema (Oct 2016)

Posted by Matt Breese on Nov 4, 2016

Find me on:

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows that overall restricted lives across medicare and health exchange formularies decreased. Additionally, a much larger percentage of PA policies are now appropriate to the product's FDA approved label


Source: MMIT data as of Q4 2016

Trends:  Recent news related to HAE treatments highlights some key trends in this therapeutic area. A handful of hereditary angioedema launches reveals the shift in drug development from manufacturers. Novel therapies incite increased prophylaxis utilization. Additionally, the recent launch of an HAE treatment for pediatric patients provides some additional options for prescribers.

In the full Reality Check on HAE treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on hereditary angioedema with key findings on clinical characteristics, HAE drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing